中草药辅助tPA溶栓治疗实验性卒中的疗效:系统评价与荟萃分析
该系统评价纳入9项动物实验,评估11种中草药辅助tPA溶栓的疗效与安全性。汇总显示中草药可改善神经功能评分、减少梗死体积、减轻脑出血和血脑屏障损伤,但结果基于动物研究需谨慎解读。
要点
- 中草药辅助tPA溶栓可改善实验性卒中神经功能评分和梗死体积。
- 中草药可减轻tPA溶栓后脑出血和血脑屏障损伤。
- 给药途径、tPA剂量和卒中模型可能影响疗效异质性。
核心结论
- 中草药辅助tPA溶栓可显著改善实验性卒中的神经功能评分和梗死体积,并减少脑出血和血脑屏障损伤。
研究设计与样本
- 系统评价与荟萃分析,检索Web of Science、PubMed和Scopus至2022年1月,纳入9项报告中草药对实验性卒中tPA溶栓疗效与安全性的研究,共涉及11种中草药。
主要发现
- 中草药改善神经功能评分(SMD 2.23,95%CI 1.42-3.04)。
- 中草药减少梗死体积(SMD 1.08,95%CI 0.62-1.54)。
- 中草药减轻脑出血(SMD 1.87,95%CI 1.34-2.4)。
- 中草药改善血脑屏障功能障碍(SMD 1.9,95%CI 1.35-2.45)。
- 亚组分析提示给药途径、tPA剂量和卒中模型可能是异质性来源并影响疗效。
关键数值与推荐
- 纳入研究质量采用CAMARADES清单评估。
- 所有结局指标使用标准化均数差(SMD)及95%置信区间评估。
- 采用Trim and fill法和Egger检验评估发表偏倚,敏感性分析检验结果稳定性。
临床怎么用
- 中草药可作为辅助治疗用于减轻急性缺血性卒中tPA溶栓后的副作用,但当前证据仅来自动物实验,临床决策需谨慎。
局限性
- 结果基于动物研究,需谨慎解读。
- 纳入研究存在异质性,可能受给药途径、tPA剂量和卒中模型影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tissue-type plasminogen activator (tPA) remains the sole FDA approved thrombolytic drug for ischemic stroke. But delayed thrombolytic therapy with tPA may increase the risk of hemorrhagic transformation. Many Chinese herbal medicines have been used as tPA helpers to enhance the capacity of tPA and minimize the risk of hemorrhagic transformation. The efficacy of Chinese herbal medicines on tPA thrombolysis is not systematically analyzed. METHODS: We searched the following three databases up to January 2022: Web of Science, PubMed, and Scopus. Studies that reported the efficacy and safety of Chinese herbal medicines on tPA thrombolysis in experimental stroke were included. The efficacy outcomes were neurological score and infarct volume, the safety outcomes were cerebral hemorrhage and blood brain barrier (BBB) damage. We used the checklist of CAMARADES to assess the quality of included studies. Standardized mean difference (SMD) with 95% confidence intervals were used to assess all the outcomes. Subgroup analyses were performed to explore the sources of heterogeneity. Trim and fill method and Egger's test were used to assess the potential publication bias. Sensitivity analyses were used to identify the stability of the results. RESULTS: A total of nine studies including 11 Chinese herbal medicines fulfilled the inclusion criteria and were subsequently analyzed. The pooled data demonstrated that Chinese herbal medicines improved neurological score (2.23 SMD, 1.42-3.04), infarct volume (1.08 SMD, 0.62-1.54), attenuated cerebral hemorrhage (1.87 SMD, 1.34-2.4), and BBB dysfunction (1.9 SMD, 1.35-2.45) following tPA thrombolysis in experimental stroke. Subgroup analysis indicated that the route of drug delivery, dosage of tPA, and stroke model used may be factors inducing heterogeneity and influencing the efficacy. CONCLUSION: Treatment with Chinese herbal medicines significantly improved neurological score and infarct volume, reduced cerebral hemorrhage and BBB damage after tPA thrombolysis. This study supports Chinese herbal medicine as an adjuvant therapy in reducing the side effects of tPA thrombolysis after acute ischemic stroke. The results should be interpreted with more caution since this article was based on animal studies.
引用
- Ye Y, Zhu YT, Xin XY, et al. Efficacy of Chinese herbal medicine for tPA thrombolysis in experimental stroke: A systematic review and meta-analysis. Phytomedicine. 2022. PMID: 35349833. doi:10.1016/j.phymed.2022.154072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。